Detailed data from a key trial of Biogen Idec Inc’s (BIIB.O) experimental multiple sclerosis drug BG-12 revealed no new safety concerns, and showed similar efficacy when given twice or three times a day, according to a summary of results to be presented at an upcoming conference. Initial results from the trial, known as DEFINE, were released in April and showed the drug, when given twice a day, cut the annualized relapse rate by 53 percent at two years compared with placebo, and cut the rate of disability progression by 38 percent. Biogen said at the time that the side effects were similar to those seen in an earlier, mid-stage trial, but did not elaborate.
